Gilead­'s Kite nabs Carl June spin­out Tmu­ni­ty af­ter neu­ro­tox kills pa­tients, forc­ing re­org — and a re­think

One of the pi­o­neers of first-gen CAR T has now swooped in to buy a sec­ond-gen cell ther­a­py play­er with some stel­lar sci­en­tif­ic ties, im­pres­sive ear­ly re­spons­es and a clin­i­cal record that in­cludes a high-pro­file blowup in the clin­ic that killed sev­er­al pa­tients.

Gilead sub Kite is putting out word to­day that it’s nailed down the buy­out of Tmu­ni­ty, a cell ther­a­py spin­out out of Penn that was de­railed by lethal tox­i­c­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER